Saída do CEO da West Pharmaceutical
Nova narrativa com cobertura limitada — ainda em formação.
Principais Movimentações
| Ticker | Setor | Variação |
|---|---|---|
| — | +4,8% |
Linha do Tempo de Sentimento
Linha do Tempo de Eventos
Hipóteses
West Pharmaceutical's Q3 2024 revenue guidance will be maintained or increased (no downward revision) despite CEO transition, with management affirming full-year 2024 outlook, demonstrating operational stability.
If West Pharmaceutical announces an internal successor within 60 days of CEO exit announcement, WST stock will recover and trade at or above pre-announcement levels by day 90, indicating market confidence in continuity.
West Pharmaceutical Services (WST) stock will experience a negative price reaction of 3-5% within 5 trading days following the CEO exit announcement due to succession uncertainty and potential disruption to strategic initiatives.
Principais Movimentações
| Ticker | Setor | Variação |
|---|---|---|
| — | +4,8% |